BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31906779)

  • 1. Intravitreal Steroid Treatment for Uveitis Associated with Dabrafenib and Trametinib for Metastatic Cutaneous Melanoma.
    Woltsche N; Kruger MA; Weger M; Wolf IH; Seidel G
    Ocul Immunol Inflamm; 2021 Jul; 29(5):845-847. PubMed ID: 31906779
    [No Abstract]   [Full Text] [Related]  

  • 2. Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report.
    Lim J; Lomax AJ; McNeil C; Harrisberg B
    Ocul Immunol Inflamm; 2018; 26(4):628-631. PubMed ID: 27892777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choroidal Neovascularization in Multifocal Choroiditis after Dabrafenib and Trametinib.
    Albertini GC; Corbelli E; Battaglia Parodi M; Bandello F
    Eur J Ophthalmol; 2017 Nov; 27(6):e184-e186. PubMed ID: 28777388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
    Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
    Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
    Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral Drug-Induced Uveitis and Epiretinal Membrane during the Treatment of a Metastatic Cutaneous Melanoma.
    Mozo Cuadrado M; Tabuenca Del Barrio L; Compains Silva E
    Ocul Immunol Inflamm; 2021 Apr; 29(3):543-545. PubMed ID: 31755788
    [No Abstract]   [Full Text] [Related]  

  • 7. Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.
    Huynh S; Lheure C; Franck N; Goldman-Lévy G; Aractingi S; Dupin N; Kramkimel N; Guégan S
    Melanoma Res; 2020 Jun; 30(3):317-320. PubMed ID: 32053122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
    Lacroix JP; Wang B
    J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report.
    Sundaram VR; Abbas T
    Medicine (Baltimore); 2018 Nov; 97(44):e12751. PubMed ID: 30383630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
    Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
    Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
    Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib.
    Rueda-Rueda T; Sánchez-Vicente JL; Moruno-Rodríguez A; Molina-Socola FE; Martínez-Borrego AC; López-Herrero F
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Sep; 93(9):458-462. PubMed ID: 29580759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
    N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
    Hauschild A; Dummer R; Schadendorf D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Haas T; Shilkrut M; Gasal E; Kefford R; Kirkwood JM; Long GV
    J Clin Oncol; 2018 Dec; 36(35):3441-3449. PubMed ID: 30343620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular toxicity due to Trametinib and Dabrafenib.
    Sarny S; Neumayer M; Kofler J; El-Shabrawi Y
    BMC Ophthalmol; 2017 Aug; 17(1):146. PubMed ID: 28818062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
    N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.